However, the glucose-independent activity of some common therapies such as insulin glargine and glimepiride is associated with increased rates of hypoglycaemia compared to GLP-1R agonists (Table 1) [18,20,42]. The gene discussed is GLP1R; the disease is Hypoglycemia.